updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
valuat growth profit
methodolog valu compani
buoy grow demand radiotherapi rt varian main
competitor elekta enjoy sale momentum next
decad particularli emerg market rt industri
consolid substanti past decad two
compani prime posit benefit believ
mid-single-digit growth marketplac
focu drug
therapi
investor seek capit futur cancer treatment
pizzazz cancer drug market growth
prospect rather attract earli stage rt
adopt latest advanc technolog allow higher
dosag precis deliveri radiat address mani
concern surround rt significantli expand potenti
rt opportun particularli attract emerg market
util rate significantli trail develop
world demograph western emerg
market drive cancer incid higher demand rt
acceler significantli yet still massiv gap
current rt instal base need meet grow
demand estim market support twice mani
platform without approach develop world standard
varian elekta stand benefit trend
forecast call close world rt equip
instal provid two compani next
decad varian exposur matur market limit
growth prospect compani scale strong suit
product allow captur major global linac
varian spin-off imag busi posit develop
segment drag perform view
limit synergi core oper varian
focu proton therapi like drag result
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
varian medic system design manufactur sell radiat
technolog use two busi segment oncolog system proton
therapi america account largest portion revenu
follow europ middl east africa asia-pacif
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first-quart result full-year
forecast strong rais fair valu
estim modestli per share mainli account
cash flow realiz sinc previou report share
ralli significantli past year stock trade
moder premium updat valuat
maintain wide moat rate firm
state clearli note previou quarter
varian forecast conserv
perplex growth estim oncolog
busi opt maintain growth
forecast saw good upsid halcyon
platform continu strength nonhardwar
busi mind compani revis guidanc
heel impress first-quart
result particularli surpris us anticip
strength inde come halcyon emerg market
software/servic furthermor alreadi
model lower long-term tax rate anoth
factor upgrad guidanc
said remain impress varian steadili strong
result especi compar uneven perform
main competitor elekta halcyon hit
emerg market adopt platform
larg expect also cost-consci develop
market surprisingli account
order far success rapidplan veloc also
larg account forecast nonetheless
compani market share gain softwar busi
valuat growth profit jan
increas fair valu estim per share
slightli revis near-term project
account time valu money
expect varian domin global posit result
captur rate roughli equal instal base
market share even split elekta elsewher
forecast varian entir instal base grow
unit current repres
roughli instal base market share
forecast geographi product mix evolv
asia-pacific/softwar servic presenc expect
oncolog platform sale america repres less
total oncolog sale
percentag point servic softwar sale
grow rate basi point higher
hardwar trend occur elsewher
although hardwar placement emerg market
still repres main portion sale
varian gradual shift toward aftermarket sale allow
gross margin expand gradual offset potenti
price pressur chang geographi mix forecast
call gross margin pariti elekta varian
varian overal cost structur remain lower
given scale compani continu see
oper leverag earn growth averag
close throughout forecast
varian deliv strong perform bottom line
gross oper margin show
improv believ compani exceed
revis earn guidanc maintain forecast
varian fair valu estim rang per share
bear-cas scenario per share bull-cas
scenario key driver forecast revenu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
flip side mani uncertainti surround
proton temper enthusiasm
uncertainti rate base scenario analysi
compani world involv
radiotherapi varian elekta account
lion share new instal siemen
bow market rt equip
character high barrier entri owe
know-how high switch cost aris
signific train cost disrupt risk start
decad ago rather fragment field
evolv essenti duopoli new entrant
decad main two player built
durabl franchis mind upgrad
varian econom moat rate wide narrow
intellectu properti
combin high herfindahl ratio signific barrier
entri moder degre rivalri posit rt
favor rel sever devic industri segment
despit potenti price pressur emerg
market custom tend cost-consci
consid degre rivalri key player
moder anticip firm engag
hardwar emerg market may end
lower opportun upsel custom
custom base razor/razor blade busi model
offer ampl opportun high-margin/high-return
aftermarket sale entir rt market expect
grow mid- high singl digit strong
stimuli firm compet aggress
growth margin expans believ entir rt
industri grow mid-single-digit rate
risk assumpt mainli deterior
 marketplac unexpect aggress price
strategi emerg market event would depress
varian growth particular given outsiz exposur
 low-single-digit growth consid
scenario like given benefit rt age platform
instal base low incent start
price war howev scenario margin stay flat
slightli declin earn growth averag
rather minuscul versu greater
histor strip benefit varian econom
moat fair valu estim declin upsid
case assum fairli rapid growth western europ rt
adopt rate pickup upgrad cycl
double-digit growth emerg market
addit margin expans varian earn grow
mid- high teen rate proton therapi wild card
valuat treatment becom mainstream could
repres radio treatment end next
decad case varian could see proton revenu rise
dramat proton servic carri particularli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
strong thank long shelf life linac averag
life span machin eight year depend
custom signific price tag train cost
associ rt equip furthermor
absenc signific bodi academ clinic data
intang asset moat sourc new entrant space
chanc establish player given
life-sav natur machin along high
risk oper oncologist familiar softwar
also
competitor
develop treatment plan share softwar
potenti entrench exist competitor
creat network effect would give varian elekta
edg get greenfield instal howev
vast major new order split two firm
forecast strengthen posit rel
remaind field becom less meaning versu
head-to-head comparison view competit
dynam stabl thu firm carri stabl moat trend
rate varian competit posit proton
improv notabl particularli roll-out
single-room platform enough affect overal
varian largest rt manufactur
market share global even domin posit
 control roughli instal
elekta second-largest player roughli fourth
world rt instal expect field becom
concentr vast major replac
instal greenfield expect go either
varian elekta stickier custom base
entri barrier also increas expect
global market share platform instal reflect
belief two firm compel
offer marketplac
view varian competit posit
two busi particularli imag strong thu
approv compani spin imag
oper focus sole radiotherapi proton
still earli stage develop
first-mov advantag import clear
futur marketplac believ varian better
posit peer space
market fragment varian main competitor
iba world-wide focus sole proton howev
iba lack deep pocket varian proton requir
signific on-going invest technolog
clinic data thu assum varian end winner
area although whether ever earn return similar
achiev linac yet determin
consid compani wide econom moat
sever moat sourc consid
expand mainli switch cost emerg
network effect varian elekta posit rel
fairli stabl switch cost alreadi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ovarian invest softwar busi
pay compani take share elekta
particularli treatment plan side
oproton potenti significantli disrupt
radio-oncolog field varian advantag
elekta pure-play proton player
virtual
untouch close exist instal
base need upgrad bode well
firm latest product introduct
ovarian spun imag busi
result dyssynergi
oproton therapi interest grow field
cost requir instal well
limit clinic data could hinder adopt
ovarian exposur freestand clinic rel
minor free clinic consolid
acquir larger hospit sever platform due
replac probabl come market entir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
varian healthi balanc sheet carri littl
debt compani cash flow robust steadi
minim concern solvenc
key concern rt industri futur
reimburs trend replac natur
 market slow adopt rt western europ
aggress competit emerg market
center medicar medicaid servic reimburs
rate mix bag industri one hand
hospit rate particularli emerg technolog
imrt receiv steadi increas free-stand
oper squeez howev long two
compani continu demonstr effect rt
anticip rather friendli industri
given low cost rt rel overal cancer
treatment industri western europ much forecast
hing abil willing central govern
invest rt equip bring usag par
 also cost-consci consum emerg
market rais risk disciplin price
world could
deterior softwar servic crucial
compon firm strategi growth stori
revenu sourc could perceiv
deploy capit payoff certain initi
varian invest proton therapi elekta
mri-en linac uncertain proton particular could
riski endeavor varian willing financ
construct proton facil expos credit risk
evidenc recent write-down scripp loan
final must awar develop outsid
cancer treatment certain emerg
treatment immuno-oncolog could dramat
alter current treatment paradigm believ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
radiotherapi remain relev even immuno-oncolog
prove disrupt forc growth trajectori may
affect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
septemb wilson took ceo follow
timothi guertin retir wilson work
compani variou capac sinc includ
presid oncolog system busi
wilson compani seem much focus
aftermarket sale critic long-term growth
term capit alloc manag decis
solid acquisit target smaller firm give
varian access emerg technolog softwar
invest proton therapi highli
uncertain payoff profil shield firm
disrupt caus emerg therapi manag
commit imag busi test
varian final spun busi believ
correct decis competit posit
imag deterior dramat right ship
would requir capit invest would distract
varian flagship rt busi
repres date owner name posit common share held report holder issuer
govern pension fund norway global
fidel manag research compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
first-quart result full-year
forecast strong rais fair valu
estim modestli per share mainli account
cash flow realiz sinc previou report share
ralli significantli past year stock trade
moder premium updat valuat
maintain wide moat rate firm
state clearli note previou quarter
varian forecast conserv
perplex growth estim oncolog
busi opt maintain growth
forecast saw good upsid halcyon
platform continu strength nonhardwar
busi mind compani revis guidanc
heel impress first-quart
result particularli surpris us anticip
strength inde come halcyon emerg market
software/servic furthermor alreadi
model lower long-term tax rate anoth
factor upgrad guidanc
said remain impress varian steadili strong
result especi compar uneven perform
main competitor elekta halcyon hit
emerg market adopt platform
larg expect also cost-consci develop
market surprisingli account
order far success rapidplan veloc also
larg account forecast nonetheless
compani market share gain softwar busi
varian deliv strong perform bottom line
gross oper margin show
improv believ compani exceed
revis earn guidanc maintain forecast
varian close book mix result
varian medic system fourth-quart result
margin expect adjust
model result compani guidanc
plan chang fair valu estim
cash flow realis sinc previou updat larg off-set
moder under-perform quarter
conservat compani guidanc
revenu earn line maintain wide
bit perplex growth forecast
oncolog busi market-
specif issu weak japan one struggl
reconcil guidanc compani excel
order growth upcom launch halcyon
china japan continu strong uptak
compani servic softwar offer see coupl
possibl explan conservat guidanc
one compani push emerg market cost-
consciou user halcyon result longer
convers cycl platform target greenfield
instal requir new bunker push revenu
growth latter year two compani lack
confid product mix potenti cannibalis
beam price sustain north american
growth heel strong perform
market develop nice firm year
also note strong order growth support
result particularli softwar uptak hyperarc
remain current trajectori believ varian
come higher end guidanc revenu
line help earn perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
varian took anoth write-off relat proton financ
busi proton order look strong go
firm receiv two order quarter one india one
china finish year million backlog
year year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
